On April 1, the Government of India announced comprehensive guidelines concerning the usage, risks, and regulation of GLP-1 (glucagon-like peptide-1) drugs. These medications are primarily designed to assist individuals with diabetes, specifically targeting type 2 diabetes, and obesity. Diabetes is a chronic condition marked by inadequate insulin production or ineffective use of insulin, leading to elevated blood sugar levels. Untreated diabetes can result in severe complications, including cardiovascular issues, kidney failure, vision loss, and amputations.

Insulin and glucagon are critical hormones produced by the pancreas, responsible for maintaining balanced blood sugar levels. Insulin facilitates the conversion of food into energy and aids in the absorption of glucose by cells, while glucagon plays a role in raising blood sugar levels when necessary. In individuals with type 2 diabetes, the dysregulation of these hormones contributes to high blood sugar levels.

Risk Factors Associated with Type 2 Diabetes

Individuals with excess body weight, a family history of diabetes, and high sugar intake are at a considerably higher risk of developing type 2 diabetes. A body mass index (BMI) exceeding 25 kg/m² is classified as obese, further exacerbating the risk for diabetes and associated non-communicable diseases. Data highlight that abdominal fat significantly increases insulin resistance, making obesity a key contributor to various health disorders, including heart disease and certain cancers.

The government clarified that there are two primary types of diabetes. Type 1 diabetes arises from an absence of insulin production by the pancreas, necessitating lifelong insulin therapy. Conversely, type 2 diabetes is characterized by the body’s inability to use insulin effectively. Preventive measures include maintaining a healthy weight, engaging in regular physical activity, adhering to a balanced diet, and avoiding tobacco use.

Mechanism and Variants of GLP-1 Drugs

GLP-1 drugs are utilized to manage both type 2 diabetes and obesity by correcting hormonal imbalances related to insulin and glucagon. These medications stimulate insulin secretion while suppressing excessive glucagon, thereby facilitating better blood sugar control. The drugs are known to delay gastric emptying, enhancing satiety and reducing appetite, which contributes to weight loss.

Recently, several GLP-1 medications have entered the Indian market, raising concerns regarding their availability through various retail and online platforms. In response, the Drug Controller General of India has increased regulatory oversight to prevent unauthorized distribution and improper usage of these drugs. Without proper medical supervision, GLP-1 drugs can lead to severe adverse effects.

Health Risks and Regulatory Measures

The press release outlined the physiological role of GLP-1 in regulating blood sugar levels post-meal. The drug mimics this hormone’s actions, stimulating further insulin release and inhibiting glucagon effect. While GLP-1 medications are beneficial, they come with potential side effects ranging from mild symptoms like nausea to serious complications such as pancreatitis and thyroid cancer. Therefore, it is imperative for patients to use these drugs only under strict medical guidance.

Regulatory measures include stringent actions against unauthorized sales and misleading advertising. Only certified medical professionals can prescribe GLP-1 drugs in India, underscoring the importance of clinical oversight. An advisory was issued in March 2026 aimed at curbing unethical marketing practices.

Inspections of various pharmacies and clinics have been conducted across the nation to enforce compliance with established protocols. Businesses found violating these guidelines may face severe penalties, including license revocation and legal repercussions. Compliance with safety standards is necessary to minimize health risks associated with GLP-1 drug usage in the population.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share